Araris, Novago and Tolremo are nominated for Strüngmann Award

(CONNECT) Three companies from Switzerland have been nominated for the Strüngmann Award, which is being presented for the second time this year. The award was established in 2024 to honor outstanding entrepreneurs who establish revolutionary technologies in the life science sector in the DACH region. According to the press release, the nominees are Araris Biotech from Au, NovaGo Therapeutics in Schlieren and TOLREMO therapeutics based in Basel. The winning team will be announced on July 3 and will receive prize money of 100,000 euros.

The founding team of Araris Biotech was nominated. The spin-off from the Paul Scherrer Institute (PSI) is developing a new generation of drugs that could revolutionize the concept of targeted cancer therapy and could also be used in other medical fields in the future. The nominees are CEO Dragan Grabulovski, CSO Philipp Spycher and CTO Isabella Attinger-Toller.

At NovaGo Therapeutics, a member of the Bio-Technopark Schlieren-Zurich, Professor Martin E. Schwab was nominated. The neuroscientist is CSO and co-founded the company in 2015. The biotech company specializes in antibody-based therapies for the regeneration of nerves and blood vessels. The company's main program focuses on the treatment of acute spinal cord injuries.

Stefanie Flückiger-Mangual is the founder and CEO of TOLREMO therapeutics in Basel. The company is pursuing a comprehensive new approach to overcoming resistance to cancer drugs.

“We are convinced of the exceptional talent in the life science industry in the DACH region and would like to use this award to highlight and promote both innovative ideas and their successful implementation,” Andreas and Thomas Strüngmann are quoted as saying. ce/gba